Treatment of cancer cells over-expressing HER2 with trastuzumab, a therapeutic antibody targeting HER2, results in inhibition of HER2-mediated mitogenic signaling and a reduction in cell proliferation (6). The gene discussed is ERBB2; the disease is cancer.